Clinical group | Total number | Age | CSF | ||
---|---|---|---|---|---|
(Females) | (Years) | QALB | Total protein (μg/ml) | Lymphocytes | |
TBE-I | |||||
with GCs treatment | 21(10) | 43.7 ± 16.2 | 12.1 ± 1.4 | 851 ± 121 | 105 ± 15.1 |
without GCs treatment | 24(11) | 829 ± 129 | 93 ± 12.1 | ||
TBE-II | 40.7 ± 16.9 | 11.3 ± 1.7 | |||
with GCs treatment | 19(10) | 811 ± 128 | 76 ± 23.4 | ||
without GCs treatment | 44.2 ± 12.8 | 11.6 ± 1.3 | 784 ± 122 | 76 ± 14.1 | |
20(9) | |||||
LNB | 39.1 ± 16.7 | 10.8 ± 1.3 | 782 ± 152 | 48.2 ± 9.3 | |
18(7) | 46.5 ± 10.3 | 9.8 ± 1.1 | |||
MS | 22(16) | 37.2 ± 13.4 | 6.5 ± 0.9 | 435 ± 163 | 5.7 ± 4.6 |
Control | |||||
Idiopathic cephalgia | 21(14) | 43.6 ± 21.4 | 6.1 ± 0.5 | 414 ± 144 | 3.7 ± 1.9 |
Idiopathic (Bell’s) facial nerve palsy | 16(10) | 45.2 ± 18.8 | 6.7 ± 1.1 | 375 ± 183 | 4.1 ± 1.2 |